Humana's withdrawal of its 2025 profit forecast due to lower than expected Medicare Advantage reimbursement rates and a high medical benefit ratio directly impacts its financial outlook. This news is likely to negatively affect investor confidence and could lead to a short-term decrease in stock price, as evidenced by the 3.75% drop in shares. The company's acknowledgment of the unachievable revised EPS growth targets further exacerbates concerns over its future profitability.